Plain-English translation of NCT06680752 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called , which is a type of cell therapy made from your own immune cells that have been specially engineered to fight blood cancer. The treatment targets cancer cells while trying to spare your healthy blood-forming cells. Researchers want to find the right dose and see how well this medication works for people whose leukemia or myelodysplastic syndrome has come back or stopped responding to other treatments.
Standard treatments don't work for everyone with these blood cancers, and patients need new options. This medication is designed to attack cancer cells in a different way than chemotherapy, potentially offering hope to people who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
In Phase 1, you would receive escalating doses of the medication to help doctors find the safest and most effective dose. In Phase 2, you would receive the chosen dose and be monitored closely to see how well the treatment works. You would have multiple clinic visits for blood tests, imaging scans, and physical exams to track how you're responding to the medication and manage any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States